Liver
The Latest
Heavy drinking tied to increased fibrosis risk in MASLD
-
by Olivia Anderson
"Episodic heavy drinking is an incredibly common pattern right now among US adults that even when it’s occasional, can be especially harmful."
Five startups reach AGA Shark Tank finals
-
by Doug Brunk
“It’s more about the inspiration than about the winner.”
New findings 'expose a critical blind spot in liver disease classification'
-
by Julia Cipriano
Routine underreporting of consumption means many patients are being misclassified as MASLD.
MRI techniques shown to improve cirrhosis diagnosis
-
by Doug Brunk
MR elastography found to provide detailed, noninvasive staging even in patients with advanced disease.
MASLD fibrosis significantly drives HCC risk, study finds
-
by Doug Brunk
Large patient-level meta-analysis clarifies how fibrosis stage shapes liver cancer risk.
FDA approves linerixibat for cholestatic pruritus in PBC
-
by Doug Brunk
Linerixibat “is an added therapy that's mechanistically different from what we have, and therefore I think that it's going to be used."
AGA updates MASLD care pathway
-
by Doug Brunk
A two-tier strategy is recommended using noninvasive tests to identify patients who require specialty evaluation.
Tirzepatide outperforms semaglutide for weight loss
-
by Julie Greenbaum
Real-world data show greater weight loss with dual incretin therapy.
Lower health literacy tied to worse MASLD
-
by Doug Brunk
Pilot study links limited health literacy to greater liver stiffness, steatosis, and obesity in a clinic cohort.
Steroids show modest 28-day benefit in severe alcohol-associated hepatitis
-
by Doug Brunk
Steroids improve early survival in severe alcohol-associated hepatitis — but long-term benefit remains uncertain.
Gastric cancer risk rises in familial adenomatous polyposis
-
by Doug Brunk
FAP patients found to have a 12-fold higher risk of gastric cancer than the general population.
Pediatric MASLD tied to early morbidity
-
by Doug Brunk
Review details rising prevalence and early fibrosis risk.
Endohepatology expands clinical reach
-
by Doug Brunk
Review details performance data, comparative trials, and persistent gaps as EUS moves deeper into hepatology practice.
Endoscopic ultrasound pushes beyond biopsy in diagnostics
-
by Doug Brunk
Review highlights advances that expand endoscopic ultrasound into precision diagnostics and personalized therapy across pancreatic and liver diseases.
Combination therapy shows promise for hepatitis D in phase 2 trial
-
by Amy Pfeiffer
"Tobevibart and elebsiran have complementary mechanisms of action."
Global MASH costs set to double by 2040
-
by Doug Brunk
A multinational modeling study projects sharp rises in advanced liver disease, deaths and health care spending tied to MASH across nine countries.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
Tiny plastics may harm gut and liver health, review finds
-
by Doug Brunk
“Our aim was to start conversations between clinicians and their patients about this emerging risk,” Dr. Priyata Dutta explained.
Cell-free DNA testing shows promise for early liver cancer detection
-
by Doug Brunk
Methylation-based cfDNA assays appear particularly promising.
ACA expansion linked to better liver disease outcomes
-
by Doug Brunk
The analysis is believed to be the first of its kind.
VCTE vs histology in MASLD, study findings
-
by Doug Brunk
The study included 3,532 adults with MASLD.
Cirrhosis, age may shape HCC risk in PSC
-
by Doug Brunk
Investigators followed 3,071 patients for a mean of 12.5 years.
Positive trends in chronic HCV mortality
-
by Doug Brunk
“DAAs have revolutionized the management of HCV by making it a curable disease.”
Tirzepatide tops semaglutide for cardiometabolic protection in MASLD
-
by Doug Brunk
The study authors recommend prospective head-to-head trials to validate the findings.
ALD-related HCC mortality surges
-
by Doug Brunk
The findings underscore the urgent need for targeted prevention strategies among high-risk group.
New score challenges old predictors
-
by Kerri Miller
"MERAGE has superior performance for predicting return to drinking (RTD) compared to HRAR in AH."
Approach to weight management in GI practice
-
by Colleen R. Kelly, MD
As gastroenterologists, we treat a number of conditions that are caused or worsened by obesity.
Exercise patterns and GI cancer risk
-
by Kerri Miller
Consistently meeting—but not exceeding—recommended activity levels offers maximal protection against digestive cancers, new research suggests.
AGA issues updated guidance on HDV management
-
by Amy Pfeiffer
An AGA panel recommended universal HDV screening for all patients with chronic HBV infection.
Sarcopenia, thrombosis, and renal dysfunction dominate cirrhosis complication updates
-
by Kerri Miller
New diagnostic approaches and treatment controversies emerge for managing advanced liver disease complications.
Open vs robotic liver resections, study results
-
by Teraya Smith
Complication rates and hospital stays were analyzed across both surgical groups.
Bringing HCC patients hope through trials, advanced treatments
-
by Jennifer Lubell
For Reena Salgia, MD, the most rewarding part about working with patients with HCC is being there for their entire journey,
Clinical research in early career academic medicine
-
by Lauren D. Feld, MD, Kathy Nguyen, Katherine Cooper, MD, Loren Galler Rabinowitz, MD, Amiko M. Uchida, MD
Many exciting opportunities and notable barriers exist to establishing a clinical research laboratory in the early career.
Alcohol hepatitis: Why females face higher risks
-
by Kathryn Wighton
Study reveals rising hepatitis rates in young adults, with females facing greater risks of cirrhosis and liver-related death
How to discuss lifestyle modifications in MASLD
-
by Newsha Nikzad, MD, Daniel J. Huynh, BS, Nikki Duong, MD
Achieving promotion for junior faculty in academic medicine: An interview with experts
-
by Vineet S. Rolston, MD, Sophie Balzora, MD, Mark A. Schattner, MD
Opting for a career in academic medicine can offer benefits such as increased autonomy and scheduling flexibility.
Hepatologist finds purpose as health equity advocate for LGBTQI+
-
by Jennifer Lubell
“As I was going through training, I didn’t think others like me existed, a gay South Asian transplant hepatologist."
Statins and the liver: Not harmful and perhaps beneficial
-
by Paul Martin, MD, Lawrence S. Friedman, MD
Recruiting gastroenterology and hepatology fellows virtually - Should we continue after the pandemic?
-
by Lara Dakhoul, MD, Tiffany Rhoden, Virginia Clark, MD
Immune checkpoint inhibitor–related gastrointestinal adverse events
-
by Joshua Kwon, MD, Paul T. Kröner, MD, MSc